Dyne Therapeutics, Inc. (DYN): Insider Trades and Fund Holdings
In the past 12 months, Dyne Therapeutics, Inc. insiders reported 1 open-market purchase worth $40K and 11 sales worth $65.7M; 11 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.
- Oct 2, 2026Insider buyDirector Brian S. Posner bought $40,000
- Sep 8, 2026Insider saleCEO John Cox sold $106,823 under a 10b5-1 plan
- Sep 8, 2026Insider saleChief Medical Officer Douglas Kerr sold $24,355 under a 10b5-1 plan
- Sep 8, 2026Insider saleChief Commercial Officer Johanna Friedl-Naderer sold $3,493 under a 10b5-1 plan
- Sep 4, 2026Insider saleChief Medical Officer Douglas Kerr sold $91,191 under a 10b5-1 plan
- Sep 4, 2026Insider saleChief Commercial Officer Johanna Friedl-Naderer sold $21,915 under a 10b5-1 plan
- Aug 14, 2026Insider saleDirector Jason P. Rhodes sold $54 million under a 10b5-1 plan
- Aug 13, 2026Insider saleDirector Jason P. Rhodes sold $11.2 million under a 10b5-1 plan
- Aug 13, 2026Insider saleCEO John Cox sold $131,032 under a 10b5-1 plan
- Aug 13, 2026Insider saleCFO Erick Lucera sold $47,225 under a 10b5-1 plan
- Aug 13, 2026Insider saleChief Medical Officer Douglas Kerr sold $40,892 under a 10b5-1 plan
- Aug 13, 2026Insider saleChief Commercial Officer Johanna Friedl-Naderer sold $5,939 under a 10b5-1 plan
- Jun 30, 2026FundRenaissance Technologies cut 32% in Q2 2026 (13F filed Aug 13, 2026)
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 6, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 6 | Brian S. PosnerDirector | ▲ BUY | $40K |
| Sep 8 | John CoxCEO | ▼ SELL10b5-1 | $107K |
| Sep 8 | Douglas KerrChief Medical Officer | ▼ SELL10b5-1 | $91K |
| Sep 8 | Douglas KerrChief Medical Officer | ▼ SELL10b5-1 | $24K |
| Sep 8 | Johanna Friedl-NadererChief Commercial Officer | ▼ SELL10b5-1 | $22K |
| Sep 8 | Johanna Friedl-NadererChief Commercial Officer | ▼ SELL10b5-1 | $3K |
| Aug 17 | Jason P. RhodesDirector | ▼ SELL10b5-1 | $54.0M |
| Aug 17 | Jason P. RhodesDirector | ▼ SELL10b5-1 | $11.2M |
| Aug 17 | John CoxCEO | ▼ SELL10b5-1 | $131K |
| Aug 17 | Erick LuceraCFO | ▼ SELL10b5-1 | $47K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Brian S. Posner | Director | 1 | $40K | 0 | $0 |
| John Cox | CEO | 0 | $0 | 2 | $238K |
| Douglas Kerr | Chief Medical Officer | 0 | $0 | 3 | $156K |
| Johanna Friedl-Naderer | Chief Commercial Officer | 0 | $0 | 3 | $31K |
| Jason P. Rhodes | Director | 0 | $0 | 2 | $65.2M |
| Erick Lucera | CFO | 0 | $0 | 1 | $47K |
Tracked funds that report DYN
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 360,572 | $8.01M | ▼ −32.4% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →